VRC01 Fab was produced and purified as previously described [40 (
link)]. eOD-N276Kif, a minimal glycan, alanine-resurfaced construct possessing only three glycosylation sites (N18, N65 and N79, eOD numbering as in PDB IDs 4JPJ and 4JPK) was designed and subsequently transfected in
HEK 293F (Invitrogen) suspension cells in the presence of the mannosidase I inhibitor kifunensine, to yield homogeneous Man
9GlcNAc
2 carbohydrates. The secreted protein was purified via its C-terminus His
6-tag by affinity chromatography using
HisTrap nickel columns (GE Healthcare), and subsequently purified to size homogeneity by
Superdex 200 gel filtration chromatography (GE Healthcare). After incubation of VRC01 Fab in molar excess of eOD-N276Kif, the complex was purified by
Superdex 200 size exclusion chromatography (GE Healthcare) and concentrated to ~5 mg/ml for crystallization trials using the automated
JCSG/IAVI/TSRI CrystalMation robotic system (Rigaku) at the Joint Center for Structural Genomics (
www.jcsg.org) at TSRI. Crystals used for data collection were obtained with 0.16 M ammonium sulfate, 20% (w/v) PEG4000, 20% (v/v) glycerol, 0.08 M sodium acetate, pH 4.6, as the mother liquor. Prior to data collection, crystals were cryoprotected in the mother liquor supplemented with 40% glycerol and subsequently fast-plunged into liquid nitrogen.
Jardine J.G., Sok D., Julien J.P., Briney B., Sarkar A., Liang C.H., Scherer E.A., Henry Dunand C.J., Adachi Y., Diwanji D., Hsueh J., Jones M., Kalyuzhniy O., Kubitz M., Spencer S., Pauthner M., Saye-Francisco K.L., Sesterhenn F., Wilson P.C., Galloway D.M., Stanfield R.L., Wilson I.A., Burton D.R, & Schief W.R. (2016). Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. PLoS Pathogens, 12(8), e1005815.